e-Drug3D

1731

LEDIPASVIR

INN
LEDIPASVIR

cas 1256388-51-8

CLASS

ANTIINFECTIVES
HEPATITIS C VIRUS (HCV) NS5A INHIBITOR

ROUTE (list)

ORAL

ATC code

J05AP51

PK parameters

Tmax 4.25 HOUR
PPB 99.8 PERCENT
t1/2 47 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET HCV NS5A

DrugCentral

Genome polyprotein UNIPROT P26663

Genome polyprotein UNIPROT P27958

Download SDF file

Carbamic acid, N-[(1S)-1-[[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9H-fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]-, methyl ester

Formula:
C49H54F2N8O6

Calculated chemical properties:

MW 889.00
NB_atoms 65
XLogP 8.61
PSA 150.817
NB_HD 4
NB_HA 14
fsp3 0.47
Lipinski(0=no;1=yes) 0

FDA
NDA 205834 (pdf not found) INN (LEDIPASVIR ; SOFOSBUVIR) HARVONI (GILEAD SCIENCES INC) APPROVAL= AP YEAR= 2014
NDA 212477 (pdf not found) INN (LEDIPASVIR ; SOFOSBUVIR) HARVONI (GILEAD SCIENCES INC) APPROVAL= AP YEAR= 2019